AR014181A1 - Formulaciones de vacuna capaces de incrementar las inmunorespuestas a los antigenos t-independientes y secuencias de deoxiribo o ribonucleoticosincluidos en dichas formulaciones; metodo para inducir inmunorespuestas a dichos t antigenos o antigenos de polisacaridos conjugados - Google Patents
Formulaciones de vacuna capaces de incrementar las inmunorespuestas a los antigenos t-independientes y secuencias de deoxiribo o ribonucleoticosincluidos en dichas formulaciones; metodo para inducir inmunorespuestas a dichos t antigenos o antigenos de polisacaridos conjugadosInfo
- Publication number
- AR014181A1 AR014181A1 ARP980106677A ARP980106677A AR014181A1 AR 014181 A1 AR014181 A1 AR 014181A1 AR P980106677 A ARP980106677 A AR P980106677A AR P980106677 A ARP980106677 A AR P980106677A AR 014181 A1 AR014181 A1 AR 014181A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigens
- immunorespuestas
- formulations
- independent
- conjugated
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- 108010060123 Conjugate Vaccines Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 229940031670 conjugate vaccine Drugs 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9727262.9A GB9727262D0 (en) | 1997-12-24 | 1997-12-24 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR014181A1 true AR014181A1 (es) | 2001-02-07 |
Family
ID=10824179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106677A AR014181A1 (es) | 1997-12-24 | 1998-12-23 | Formulaciones de vacuna capaces de incrementar las inmunorespuestas a los antigenos t-independientes y secuencias de deoxiribo o ribonucleoticosincluidos en dichas formulaciones; metodo para inducir inmunorespuestas a dichos t antigenos o antigenos de polisacaridos conjugados |
| ARP980106678A AR014182A1 (es) | 1997-12-24 | 1998-12-23 | Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106678A AR014182A1 (es) | 1997-12-24 | 1998-12-23 | Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP1040123A2 (https=) |
| JP (2) | JP2001527091A (https=) |
| KR (2) | KR20010033618A (https=) |
| CN (2) | CN1284884A (https=) |
| AR (2) | AR014181A1 (https=) |
| AT (1) | ATE310535T1 (https=) |
| AU (2) | AU729336B2 (https=) |
| BR (2) | BR9814487A (https=) |
| CA (2) | CA2315276A1 (https=) |
| CO (2) | CO5070644A1 (https=) |
| DE (1) | DE69832521T2 (https=) |
| ES (1) | ES2251124T3 (https=) |
| GB (1) | GB9727262D0 (https=) |
| HU (2) | HUP0100526A2 (https=) |
| IL (2) | IL136446A0 (https=) |
| NO (2) | NO20003302L (https=) |
| NZ (2) | NZ505107A (https=) |
| PL (2) | PL341761A1 (https=) |
| TR (2) | TR200001946T2 (https=) |
| WO (2) | WO1999033488A2 (https=) |
| ZA (2) | ZA9811848B (https=) |
Families Citing this family (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6908757B1 (en) | 1998-03-26 | 2005-06-21 | The Procter & Gamble Company | Serine protease variants having amino acid deletions and substitutions |
| PT1077722E (pt) | 1998-05-22 | 2006-12-29 | Coley Pharm Group Inc | Produtos e composições para utilização na indução da imunidade mucosal |
| BR9910749A (pt) | 1998-05-29 | 2001-02-13 | Chiron Corp | Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7083796B2 (en) | 2000-06-20 | 2006-08-01 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| JP4812942B2 (ja) * | 1999-02-26 | 2011-11-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強 |
| ES2275499T3 (es) * | 1999-03-19 | 2007-06-16 | Glaxosmithkline Biologicals S.A. | Vacuna contra streptococcus pneumoniae. |
| YU72901A (sh) | 1999-04-02 | 2004-07-15 | Corixa Corporation | Preparati za primenu u terapiji i dijagnozi raka pluća |
| DE60014076T2 (de) * | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
| US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| WO2000062802A2 (en) * | 1999-04-20 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Vaccine comprising rsv antigen and cpg oligonucleotide |
| DE60023300T2 (de) * | 1999-06-29 | 2006-07-06 | Glaxosmithkline Biologicals S.A. | Verwendung von cpg als adjuvans für hivimpstoff |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US6946128B1 (en) | 1999-07-22 | 2005-09-20 | The Procter & Gamble Company | Protease conjugates having sterically protected epitope regions |
| CA2379712A1 (en) | 1999-07-22 | 2001-02-01 | The Procter & Gamble Company | Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions |
| CZ2002171A3 (cs) | 1999-07-22 | 2002-06-12 | The Procter & Gamble Company | Proteinázový konjugát, čistící prostředek a prostředek osobní péče |
| CA2376045A1 (en) | 1999-07-22 | 2001-02-01 | The Procter & Gamble Company | Subtilisin protease variants having amino acid substitutions in defined epitope regions |
| CA2380947C (en) | 1999-08-19 | 2011-11-01 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| GB9925559D0 (en) * | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
| US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| CZ303468B6 (cs) | 2000-02-23 | 2012-10-03 | Smithkline Beecham Biologicals S. A. | Imunogenní smes a farmaceutická smes |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
| US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
| US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
| US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| EP1278855B1 (en) | 2000-04-21 | 2008-03-12 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| EP2000144A1 (en) | 2000-05-19 | 2008-12-10 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds |
| AUPQ761200A0 (en) | 2000-05-19 | 2000-06-15 | Hunter Immunology Limited | Compositions and methods for treatment of mucosal infections |
| DK1296711T3 (da) | 2000-06-26 | 2006-08-28 | Stressgen Biotechnologies Corp | HPV-E7 til behandling af humant papillomavirus |
| JP2004513615A (ja) | 2000-06-28 | 2004-05-13 | コリクサ コーポレイション | 肺癌の治療および診断のための組成物および方法 |
| JP4188687B2 (ja) | 2000-12-27 | 2008-11-26 | ダイナバックス テクノロジーズ コーポレイション | 免疫変調ポリヌクレオチド及びその使用法 |
| WO2002089747A2 (en) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| CA2451974C (en) | 2001-06-21 | 2014-10-14 | Karen L. Fearon | Chimeric immunomodulatory compounds and methods of using the same |
| JP4607452B2 (ja) | 2001-08-07 | 2011-01-05 | ダイナバックス テクノロジーズ コーポレイション | 免疫調節性組成物、製剤およびその使用方法 |
| IL160809A0 (en) | 2001-09-20 | 2004-08-31 | Glaxo Group Ltd | HIV-gag CODON-OPTIMISED DNA VACCINES |
| CA2860702C (en) | 2001-12-17 | 2019-02-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
| CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| CA2484941A1 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
| EP2402026A3 (en) | 2002-09-13 | 2012-04-18 | Intercell AG | Method for isolating hepatitis C virus peptides |
| PT2241325E (pt) | 2002-10-29 | 2012-04-12 | Coley Pharm Gmbh | Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c |
| EP1578954A4 (en) | 2002-12-11 | 2010-08-11 | Coley Pharm Group Inc | 5'-CPG NUCLEIC ACIDS AND USE METHOD |
| KR100525321B1 (ko) * | 2002-12-13 | 2005-11-02 | 안웅식 | 파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물 |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| PT1992635E (pt) | 2002-12-23 | 2012-03-20 | Dynavax Tech Corp | Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos |
| CA2512108C (en) | 2003-01-06 | 2013-04-02 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| ATE485056T1 (de) * | 2003-03-24 | 2010-11-15 | Intercell Ag | Verbesserte impfstoffe |
| CN100355453C (zh) * | 2003-03-24 | 2007-12-19 | 英特塞尔股份公司 | 改进的疫苗 |
| JP4850512B2 (ja) * | 2003-05-15 | 2012-01-11 | 独立行政法人科学技術振興機構 | 免疫刺激剤 |
| JP2007528838A (ja) * | 2003-12-24 | 2007-10-18 | ライデン ユニバーシティ メディカル センター | 腫瘍特異的ワクチンとしての合成タンパク質 |
| AU2005285513B2 (en) | 2004-05-25 | 2011-02-24 | Oregon Health And Science University | SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors |
| DK3312272T3 (da) | 2004-10-08 | 2019-12-02 | Us Gov Health & Human Services | Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner |
| EP2386314A1 (en) | 2005-03-31 | 2011-11-16 | GlaxoSmithKline Biologicals SA | Vaccines against chlamydial infection |
| EP2426141B1 (en) | 2005-04-29 | 2014-10-01 | GlaxoSmithKline Biologicals S.A. | Method for preventing or treating M tuberculosis infection |
| US9259463B2 (en) | 2006-01-16 | 2016-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Chlamydia vaccine |
| CN101421306B (zh) * | 2006-04-19 | 2013-09-18 | 浦项工科大学校产学协力团 | 用于治疗和预防子宫颈癌的包含hpv多肽和免疫增强肽的组合物 |
| WO2008094200A2 (en) * | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc | Chimeric virus-like particles |
| US9439959B2 (en) | 2006-07-27 | 2016-09-13 | Takeda Vaccines, Inc. | Chimeric influenza virus-like particles |
| ES2621211T3 (es) | 2007-04-04 | 2017-07-03 | Infectious Disease Research Institute | Composiciones inmunogénicas que comprenden polipéptidos de mycobacterium tuberculosis y fusiones de los mismos |
| US8518903B2 (en) | 2007-04-19 | 2013-08-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists |
| US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
| BRPI0811228A2 (pt) | 2007-05-24 | 2014-10-21 | Glaxonsmithkline Biolog S A | Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica. |
| JP2008308474A (ja) * | 2007-06-18 | 2008-12-25 | Nitto Denko Corp | 抗原ペプチド製剤の調製方法 |
| ES2725450T3 (es) | 2007-07-02 | 2019-09-24 | Etubics Corp | Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples |
| NZ599777A (en) | 2007-11-07 | 2013-09-27 | Celldex Therapeutics Inc | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| PL2222710T3 (pl) | 2007-12-24 | 2017-01-31 | Id Biomedical Corporation Of Quebec | Rekombinowane antygeny rsv |
| EP2374813A1 (en) | 2008-12-03 | 2011-10-12 | Proyecto de Biomedicina Cima, S.L. | Use of phenol-soluble modulins for vaccine development |
| CA2653478A1 (en) * | 2009-01-23 | 2010-07-23 | Gregg Martin | Automated wash system for industrial vehicles |
| AU2010243285B2 (en) | 2009-04-30 | 2013-06-06 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| AU2010264686A1 (en) | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine |
| MX2012000035A (es) | 2009-06-24 | 2012-02-28 | Id Biomedical Corp Quebec | Antigenos de virus de sincicio respiratorio recombinantes. |
| EP4218799A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
| WO2011056899A2 (en) | 2009-11-03 | 2011-05-12 | Ligocyte Pharmaceuticals, Inc. | Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps |
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| EP3165540A1 (en) | 2010-04-13 | 2017-05-10 | Celldex Therapeutics, Inc. | Antibodies that bind human cd27 and uses thereof |
| US9072760B2 (en) | 2010-09-24 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
| US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
| WO2012057904A1 (en) | 2010-10-27 | 2012-05-03 | Infectious Disease Research Institute | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity |
| US20120114688A1 (en) | 2010-11-08 | 2012-05-10 | Infectious Disease Research Institute | Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis |
| TWI507413B (zh) * | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
| PL2651436T3 (pl) | 2010-12-14 | 2016-10-31 | Kompozycja antygenów mykobakteryjnych | |
| WO2012088425A2 (en) | 2010-12-22 | 2012-06-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
| EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
| GB201106357D0 (en) | 2011-04-14 | 2011-06-01 | Pessi Antonello | Composition and uses thereof |
| DK2707385T3 (da) | 2011-05-13 | 2017-11-20 | Glaxosmithkline Biologicals Sa | RSV-F-præfusionsantigener |
| CA2837651A1 (en) | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| CN102343103B (zh) * | 2011-07-26 | 2016-04-27 | 马丁 | 人乳头状瘤病毒16型三肽疫苗的筛选和验证及持续表达hpv16 e5, e6, e7的肿瘤动物模型的构建 |
| EP2666785A1 (en) | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
| MX385774B (es) | 2012-08-03 | 2025-03-18 | Infectious Disease Res Inst | Composiciones para usarse en el tratamiento de una infección activa por mycobacterium tuberculosis. |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| WO2014024026A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against rsv and b. pertussis |
| WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
| WO2014052453A1 (en) * | 2012-09-25 | 2014-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
| WO2014165291A1 (en) | 2013-03-12 | 2014-10-09 | The Trustees Of The University Of Pennsylvania | Improved vaccines for human papilloma virus and methods for using the same |
| FI2970398T3 (fi) | 2013-03-13 | 2024-08-06 | Us Health | Rsv f -prefuusioproteiineja ja niiden käyttö |
| UY35418A (es) | 2013-03-15 | 2014-10-31 | Glaxosmithkline Biolog Sa | Vacuna que proporciona protección frente a diferentes Picornavirus humanos. |
| EP2978447B1 (en) | 2013-03-28 | 2019-05-08 | Infectious Disease Research Institute | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis |
| AU2014304545A1 (en) | 2013-08-05 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
| EP2952893A1 (en) | 2014-06-04 | 2015-12-09 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Method for detecting antibody-secreting B cells specific for HLA |
| CN106659777A (zh) | 2014-06-13 | 2017-05-10 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合产品 |
| MA40920A (fr) | 2014-11-07 | 2017-09-12 | Takeda Vaccines Inc | Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci |
| AR102548A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso |
| CN113563468A (zh) | 2014-12-19 | 2021-10-29 | 雷根尼桑斯公司 | 结合人c6的抗体及其用途 |
| KR102193635B1 (ko) | 2015-01-09 | 2020-12-21 | 이투빅스 코포레이션 | 복합 면역요법을 위한 방법 및 조성물 |
| AU2015384786B2 (en) | 2015-03-03 | 2020-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Display platform from bacterial spore coat proteins |
| US20180044429A1 (en) | 2015-03-09 | 2018-02-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| WO2016172249A1 (en) | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| MX375989B (es) | 2015-05-26 | 2025-03-07 | Ohio State Innovation Foundation | Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina. |
| CN106543272A (zh) * | 2015-09-18 | 2017-03-29 | 江苏众红生物工程创药研究院有限公司 | 多功能标签融合蛋白及其表达方法和应用 |
| US12297266B2 (en) | 2016-04-18 | 2025-05-13 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human CD40 and uses thereof |
| KR20190009308A (ko) | 2016-05-21 | 2019-01-28 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 2차 결핵 및 비결핵성 마이코박테리아 감염을 치료하기 위한 조성물 및 방법 |
| CN109890408A (zh) | 2016-05-27 | 2019-06-14 | 埃特彼塞斯公司 | 新表位疫苗组合物及其使用方法 |
| BR112019004913B1 (pt) | 2016-09-16 | 2022-07-12 | Infectious Disease Research Institute | Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra |
| US11084850B2 (en) | 2016-12-16 | 2021-08-10 | The Pirbright Institute | Recombinant prefusion RSV F proteins and uses thereof |
| WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
| UA129243C2 (uk) | 2017-04-19 | 2025-02-26 | Інстітьют Фо Рісьорч Ін Біомедцін | Антитіло, що зв'язується зі спорозоїтами p. falciparum |
| JP2020524143A (ja) | 2017-06-15 | 2020-08-13 | インフェクシャス ディズィーズ リサーチ インスティチュート | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
| US11123415B2 (en) | 2017-08-16 | 2021-09-21 | Ohio State Innovation Foundation | Nanoparticle compositions for Salmonella vaccines |
| MX2020004543A (es) | 2017-11-03 | 2020-09-18 | Takeda Vaccines Inc | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. |
| WO2019147925A1 (en) | 2018-01-26 | 2019-08-01 | Nantcell, Inc. | Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy |
| US11459393B2 (en) | 2018-04-17 | 2022-10-04 | Celldex Therapeutics, Inc. | Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs |
| WO2020016322A1 (en) | 2018-07-19 | 2020-01-23 | Glaxosmithkline Biologicals Sa | Processes for preparing dried polysaccharides |
| CN110004150B (zh) * | 2018-08-01 | 2023-03-10 | 中国农业科学院兰州兽医研究所 | 一种具有免疫增强活性的CpG寡聚核苷酸序列及其应用 |
| CN111315407B (zh) | 2018-09-11 | 2023-05-02 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
| CN109675028A (zh) * | 2019-03-01 | 2019-04-26 | 龙阔（苏州）生物工程有限公司 | 疫苗佐剂及其制备方法和应用及猪繁殖与呼吸综合征疫苗 |
| CN109985234A (zh) * | 2019-04-12 | 2019-07-09 | 南华大学 | 一种梅毒螺旋体dna疫苗及其应用 |
| KR20220146451A (ko) * | 2020-01-17 | 2022-11-01 | 인벤트프라이즈 엘엘씨 | 다가 스트렙토코커스 백신 |
| CN114075293B (zh) * | 2020-08-14 | 2022-11-15 | 长沙诺盟生物医药有限公司 | 包含突变的hpv16 e6蛋白的融合蛋白和疫苗组合物 |
| AU2021337493A1 (en) | 2020-09-04 | 2023-05-18 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
| CA3214853A1 (en) | 2021-04-09 | 2022-10-13 | Celidex Therapeutics, Inc. | Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof |
| WO2023077521A1 (en) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
| WO2023114727A1 (en) | 2021-12-13 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacteriophage lambda-vaccine system |
| EP4583841A1 (en) | 2022-09-09 | 2025-07-16 | Access to Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
| CN121219315A (zh) | 2023-03-03 | 2025-12-26 | 塞德斯医疗公司 | 抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE466259B (sv) * | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| AUPN015794A0 (en) * | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
| GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| WO1998037919A1 (en) * | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
-
1997
- 1997-12-24 GB GBGB9727262.9A patent/GB9727262D0/en not_active Ceased
-
1998
- 1998-12-18 CA CA002315276A patent/CA2315276A1/en not_active Abandoned
- 1998-12-18 KR KR1020007007131A patent/KR20010033618A/ko not_active Withdrawn
- 1998-12-18 AT AT98966705T patent/ATE310535T1/de not_active IP Right Cessation
- 1998-12-18 ES ES98966705T patent/ES2251124T3/es not_active Expired - Lifetime
- 1998-12-18 CA CA2314186A patent/CA2314186C/en not_active Expired - Fee Related
- 1998-12-18 IL IL13644698A patent/IL136446A0/xx unknown
- 1998-12-18 JP JP2000526542A patent/JP2001527091A/ja active Pending
- 1998-12-18 EP EP98966706A patent/EP1040123A2/en not_active Withdrawn
- 1998-12-18 TR TR2000/01946T patent/TR200001946T2/xx unknown
- 1998-12-18 CN CN98813794A patent/CN1284884A/zh active Pending
- 1998-12-18 CN CN98813795A patent/CN1284885A/zh active Pending
- 1998-12-18 IL IL13644798A patent/IL136447A0/xx unknown
- 1998-12-18 TR TR2000/01835T patent/TR200001835T2/xx unknown
- 1998-12-18 AU AU24191/99A patent/AU729336B2/en not_active Ceased
- 1998-12-18 HU HU0100526A patent/HUP0100526A2/hu unknown
- 1998-12-18 WO PCT/EP1998/008562 patent/WO1999033488A2/en not_active Ceased
- 1998-12-18 WO PCT/EP1998/008563 patent/WO1999033868A2/en not_active Ceased
- 1998-12-18 EP EP98966705A patent/EP1039930B1/en not_active Expired - Lifetime
- 1998-12-18 KR KR1020007007126A patent/KR20010033613A/ko not_active Withdrawn
- 1998-12-18 JP JP2000526239A patent/JP2001527050A/ja active Pending
- 1998-12-18 NZ NZ505107A patent/NZ505107A/xx not_active IP Right Cessation
- 1998-12-18 DE DE69832521T patent/DE69832521T2/de not_active Expired - Lifetime
- 1998-12-18 BR BR9814487-1A patent/BR9814487A/pt not_active IP Right Cessation
- 1998-12-18 PL PL98341761A patent/PL341761A1/xx unknown
- 1998-12-18 PL PL98341698A patent/PL341698A1/xx unknown
- 1998-12-18 NZ NZ505108A patent/NZ505108A/xx unknown
- 1998-12-18 BR BR9814483-9A patent/BR9814483A/pt not_active Application Discontinuation
- 1998-12-18 AU AU24190/99A patent/AU736099B2/en not_active Ceased
- 1998-12-18 HU HU0103085A patent/HUP0103085A3/hu unknown
- 1998-12-23 AR ARP980106677A patent/AR014181A1/es not_active Application Discontinuation
- 1998-12-23 ZA ZA9811848A patent/ZA9811848B/xx unknown
- 1998-12-23 AR ARP980106678A patent/AR014182A1/es not_active Application Discontinuation
- 1998-12-23 ZA ZA9811849A patent/ZA9811849B/xx unknown
- 1998-12-24 CO CO98076596A patent/CO5070644A1/es unknown
- 1998-12-24 CO CO98076598A patent/CO5070674A1/es unknown
-
2000
- 2000-06-23 NO NO20003302A patent/NO20003302L/no not_active Application Discontinuation
- 2000-06-23 NO NO20003303A patent/NO20003303L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR014181A1 (es) | Formulaciones de vacuna capaces de incrementar las inmunorespuestas a los antigenos t-independientes y secuencias de deoxiribo o ribonucleoticosincluidos en dichas formulaciones; metodo para inducir inmunorespuestas a dichos t antigenos o antigenos de polisacaridos conjugados | |
| DZ2462A1 (fr) | Vaccin antigrippal. | |
| IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
| DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
| BR9910643A (pt) | Processos e produtos para a indução de imunidadede mucosa | |
| CY1120882T1 (el) | Επισημασμενα νουκλεοτιδια | |
| CY1108526T1 (el) | Εμβολια εναντι καρκινων | |
| CY1105364T1 (el) | Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης | |
| WO2004053104A3 (en) | 5’ cpg nucleic acids and methods of use | |
| AR026994A1 (es) | Nuevas construcciones de expresion en plantas. | |
| BRPI9809791B8 (pt) | compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos | |
| DK1104306T3 (da) | Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf | |
| EP1017799A4 (en) | Mutant mhc class i molecules | |
| ES2058893T3 (es) | Procedimientos mejorados para la amplificacion de adn in vitro y para clonacion y cartografia de genomas. | |
| DK0973921T3 (da) | 2-Deoxyglucose-6-phosphat (2-DOG-6-P)-phosphatase-DNA-sekvenser som selektionsmarkør i planter | |
| ES2151506T3 (es) | Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos. | |
| NZ514228A (en) | Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation | |
| ES2042737T3 (es) | Un procedimiento para la preparacion de un glucosido de antraciclina. | |
| BR9914163A (pt) | Agente para melhorar a potência excretora da bexiga urinária, uso de um composto de amina do tipo não carbamato que tenha uma ação inibidora de acetilcolinesterase, e, método para melhorar a potência excretora da bexiga urinária | |
| AR011527A1 (es) | Metodo para mejorar la eficiencia de la transformacion | |
| WO2000061766A3 (en) | Telomerase-specific cancer vaccine | |
| CO5300406A1 (es) | Vacuna | |
| ES2184987T3 (es) | Formas de administracion solidas de liberacion instantanea y procedimiento para su preparacion. | |
| CY1107845T1 (el) | Γενετικα εμβολια με ανοσοενισχυτικο | |
| ES2176920T3 (es) | Composiciones para el tinte de las fibras queratinicas que contienen para-aminofenoles, procedimiento de tinte, nuevos para-aminofenoles y su procedimiento de preparacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |